New Preclinical Data on Tumor Treating Fields to be presented at the American Association for Cancer Research Annual Meeting 2015

ST. HELIER, Jersey–(BUSINESS WIRE)–Novocure, a commercial stage oncology company, announced today that four preclinical abstracts will be presented at the American Association for Cancer Research (AACR) Annual Meeting 2015 in Philadelphia to be held April 18-22, 2015. The four abstracts highlight the latest understanding of the mechanism of action of Tumor Treating Fields, or TTFields. …

Intersect ENT Appoints Kieran Gallahue and Tony Vernon to Board of Directors

April 09, 2015 07:35 PM Eastern Daylight Time MENLO PARK, Calif.–(BUSINESS WIRE)–Intersect ENT, Inc. (NASDAQ: XENT), a company dedicated to improving the quality of life for patients with ear, nose and throat conditions, today announced the appointment of Kieran T. Gallahue and W. Anthony Vernon to the company’s board of directors. Mr. Gallahue will serve …

Novocure Announces Japanese Approval of Optune (the NovoTTF-100A System) for Treatment of Recurrent Glioblastoma

Approval provides Japanese recurrent glioblastoma patients with a new, effective and safe treatment option ST. HELIER, Jersey–(BUSINESS WIRE)–Novocure, a commercial stage oncology company, announced today that the Japanese Ministry of Health, Labour and Welfare (MHLW) has approved Optune™, a Tumor Treating Fields (TTFields) delivery device, for the treatment of patients with recurrent glioblastoma (GBM). “This …

Novocure Enrolls the First Patient in its Phase II STELLAR Trial of Tumor Treating Fields Together with Pemetrexed and Cisplatin or Carboplatin for the Treatment of Malignant Mesothelioma

STELLAR will test the efficacy and safety of Tumor Treating Fields applied to the thorax together with standard of care chemotherapy for treatment of mesothelioma ST. HELIER, Jersey–(BUSINESS WIRE)–Novocure, a commercial stage oncology company, announced today that the first patient has been enrolled in the STELLAR trial, an open-label, single-arm Phase II trial of Tumor …

Novocure Announces the Completion of Enrollment of its PANOVA Trial of Tumor Treating Fields Plus Gemcitabine for Treatment of Pancreatic Cancer

The PANOVA trial will now be expanded to treat an additional twenty advanced pancreatic cancer patients with concomitant TTFields, gemcitabine and nab-paclitaxel ST. HELIER, Jersey–(BUSINESS WIRE)–Novocure, a commercial stage oncology company, announced today that the last patient has been enrolled in the PANOVA trial, an open-label phase II clinical trial of Tumor Treating Fields (TTFields) …

Novocure Announces $100 Million Term Loan Agreement with Pharmakon Advisors

ST. HELIER, Jersey–(BUSINESS WIRE)–Novocure, a commercial stage oncology company, announced today that it has entered into a term loan agreement with an investment fund managed by Pharmakon Advisors LP. The agreement provides Novocure with up to $100 million of available borrowing capacity. Under the terms of the agreement, Pharmakon will provide $25 million at closing. …